Global cancer control: responding to the growing burden, rising costs and inequalities in access

Prager, Gerald W.; Braga, Sofía; Bystricky, B.; Qvortrup, Camilla; Criscitiello, Carmen; Esin, Ece; Sonke, Gabe S.; Martinez, G. Argiles; Frenel, Jean-Sébastien; Karamouzis, Michalis V.; Strijbos, Michiel; Yazıcı, Ozan; Bossi, Paolo; Banerjee, Susana; Troiani, Teresa; Eniu, Alexandru; Ciardiello, Fortunato; Tabernero, Josep; Zielinski, Christoph; Casali, Paolo G.; Cardoso, Fátima; Douillard, Jean Yves; Jezdic, S.; McGregor, Keith; Bricalli, Gracemarie; Vyas, Malvika; Ilbawi, André

doi:10.1136/esmoopen-2017-000285

Cited by 219 publications

(206 citation statements)

References 22 publications

Supporting

Mentioning

188

Contrasting

Unclassified

Order By: Relevance

“…Many low‐income and middle‐income countries, particularly upper‐middle countries, need to fund their public health systems to provide quality, multidisciplinary cancer care. National cancer control programs will be crucial . However, allocation of funds to cancer should not divert resources away from other diseases.…”

Section: Funding and Partnershipsmentioning

confidence: 99%

See 1 more Smart Citation

Enhancing global access to cancer medicines

Cortés

Peréz-García

Llombart-Cussac

et al. 2020

CA A Cancer J Clinicians

Self Cite

153

108

View full text Add to dashboard Cite

Globally, cancer is the second leading cause of death, with numbers greatly exceeding those for human immunodeficiency virus/acquired immunodeficiency syndrome, tuberculosis, and malaria combined. Limited access to timely diagnosis, to affordable, effective treatment, and to high‐quality care are just some of the factors that lead to disparities in cancer survival between countries and within countries. In this article, the authors consider various factors that prevent access to cancer medicines (particularly access to essential cancer medicines). Even if an essential cancer medicine is included on a national medicines list, cost might preclude its use, it might be prescribed or used inappropriately, weak infrastructure might prevent it being accessed by those who could benefit, or quality might not be guaranteed. Potential strategies to address the access problems are discussed, including universal health coverage for essential cancer medicines, fairer methods for pricing cancer medicines, reducing development costs, optimizing regulation, and improving reliability in the global supply chain. Optimizing schedules for cancer therapy could reduce not only costs, but also adverse events, and improve access. More and better biomarkers are required to target patients who are most likely to benefit from cancer medicines. The optimum use of cancer medicines depends on the effective delivery of several services allied to oncology (including laboratory, imaging, surgery, and radiotherapy). Investment is necessary in all aspects of cancer care, from these supportive services to technologies, and the training of health care workers and other staff.

show abstract

Section: Funding and Partnershipsmentioning

confidence: 99%

“…National cancer control programs will be crucial. 118 However, allocation of funds to cancer should not divert resources away from other diseases.…”

Section: Digital Medicinementioning

confidence: 99%

Enhancing global access to cancer medicines

Cortés

Peréz-García

Llombart-Cussac

et al. 2020

CA A Cancer J Clinicians

Self Cite

153

108

View full text Add to dashboard Cite

show abstract

“…Particularly, in low-income and middle-income countries (LMICs), the disease management remains strenuous and the burden is greatest, where almost 75% of cancer deaths occur and the number of cancer cases is increasing steadily. It is estimated that cancer incidence will double by the year 2035 [1].…”

Section: Introductionmentioning

confidence: 99%

Antiproliferative effects on tumor cells of the synthesized gold nanoparticles against Hep2 liver cancer cell line

R¹,

Iyer²

2020

Egypt Liver Journal

View full text Add to dashboard Cite

Background: Currently, nanomaterials (NMs) research and development is at a fastest pace due to the enhanced implication in different areas of applications. The synthesis of such NMs through biosynthesis methods is gaining much importance because of low cost involved and environment-friendly approach. In this present study, the nanoparticles (NPs) are synthesized using a medicinal plant, with anticancer properties so as to incorporate the therapeutic activity within the NPs, such that the NPs will have the attributes of NMs alongside the phytoactivity. Results: The synthesis of gold nanoparticles (AuNPs) using Graviola, the fruit of Annona muricata (Ramaphal fruit) commonly referred as Mullu seetha fruit (Tamil), was successfully carried out. The initial confirmations of the NPs were using UV-vis spectra, which showed the characteristic peak for the NPs. HRSEM analysis gave an insight on the size and morphology of the NPs. The zeta potential was measured to check the stability of the NPs. The cytotoxicity was carried out in VERO cell line and anticancer study in Hep2 liver cancer cell line. The surface plasmon resonance (SPR) band showed the characteristic peak at 536 nm for the AuNPs. In SEM micrographs, the size was ranging between 20 and 30 nm, on an average of 15 nm with spherical morphology. On the various tested concentrations in VERO cell line, the nanoparticles were non-toxic to the cells. The anticancer study gave an IC50 value at 10.94 μg/ml. Conclusions:The NPs showed anticancer activity in treated Hep2 liver cancer cell line and as well as commendable non-toxic effect on normal VERO cell line. The results pose a positive impact to expand further studies in the development of potential drug molecules to tackle the disease of interest.

show abstract

“…Cancer remains the principal cause of death in the world, regardless of economic or nancial status of the respective nations. 1 Clinical cancer treatment is heavily dependent upon chemotherapy in conjunction with radiation therapy and surgery, with immunotherapy playing a supportive role. Despite major advances in these treatment modules, high instances of tumor relapse and long-term permanent side effects remain unaddressed.…”

Section: Introductionmentioning

confidence: 99%

Formulation, characterization and evaluation of morusin loaded niosomes for potentiation of anticancer therapy

et al. 2018

View full text Add to dashboard Cite

Morusin, a water-insoluble prenylated flavonoid is known for its numerous medicinal properties. It manifests its anticancer potential by suppression of genes involved in tumor progression. However, poor solubility of the drug results in low bioavailability and rapid degradation thus hindering its clinical utilization. In order to overcome this, we have synthesized a niosome system composed of non-ionic surfactant span 60 and cholesterol using a thin-layer evaporation technique to improve the aqueousphase solubility of the drug. Highly cytocompatible niosomes of 479 nm average size with smooth and uniform spherical morphology were synthesized in a facile manner. Unlike free morusin, nanomorusin was found to be freely dispersible in aqueous media. Having an extremely high drug entrapment efficiency (97%), controlled and sustained release of morusin resulting in enhanced therapeutic efficacy was observed in cancer cell lines of 4 different lineages. The results demonstrate that the morusinniosome system is a promising strategy for enhanced anti-cancer activity against multiple cancer types and could be an indispensable tool for future targeted chemotherapeutic strategies.

show abstract

Global cancer control: responding to the growing burden, rising costs and inequalities in access

Cited by 219 publications

References 22 publications

Enhancing global access to cancer medicines

Enhancing global access to cancer medicines

Antiproliferative effects on tumor cells of the synthesized gold nanoparticles against Hep2 liver cancer cell line

Formulation, characterization and evaluation of morusin loaded niosomes for potentiation of anticancer therapy

Contact Info

Product

Resources

About